Johnson & Johnson’s MedTech segment, representing roughly 36% of total revenue, posted $8.93 billion in Q2 2026 with 4.5% year-over-year growth, below the pace of the Innovative Medicine business amid softer cardiovascular sales from electrophysiology competition and lower Abiomed volumes, partially offset by Shockwave strength. Analysts currently model Q3 MedTech near $8.78 billion, with expectations for a second-half rebound driven by accelerating surgery, vision, and orthopedics performance plus modest cardiovascular improvement, though persistent China volume-based procurement pressure and pulsed-field ablation competition remain headwinds. The company raised full-year 2026 sales guidance in July, and Q3 results scheduled for October 13 will provide the key data point for this market.